An­oth­er three biotechs are set to de­but on Nas­daq as com­bined in­dus­try raise tops $14B

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

De­spite an IPO slow­down in the third quar­ter, it’s be­com­ing ap­par­ent that Q4 will again see an ac­tive biotech mar­ket bare­ly a week in­to Oc­to­ber.

Two more com­pa­nies priced their ini­tial pub­lic of­fer­ings late Thurs­day night in Pyx­is On­col­o­gy and Iso­Plex­is. Pyx­is led the way by launch­ing at $16 per share and with a $168 mil­lion raise, while Iso­Plex­is fol­lowed up with a $15 de­but and $125 mil­lion in IPO cash.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER